Clinical Trial

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Study acronym: TORRONTES
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Protocol Amendment History 6 changes
notable Trial sites expanded: 63 -> 71 locations 2026-08-07
notable Trial sites expanded: 56 -> 63 locations 2026-07-25
notable Trial sites expanded: 48 -> 56 locations 2026-07-11
notable Trial sites expanded: 9 -> 48 locations 2026-07-01
critical Recruitment opened 2026-05-05
notable Trial sites expanded: 0 -> 9 locations 2026-05-05
Trial Details
NCT Number NCT07496567
Lead Sponsor EyeBiotech Ltd.
Conditions Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Enrollment 960 participants
Start Date 2026-04-15
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-06